Drug news
Merck KGaA returns rights to safinamide the Parkinsons treatment to Newron Pharma
Merck KGaA will return all rights to the Parkinson's disease drug ,safinamide, to its developer, Newron Pharmaceuticals. The treatment's potential commercial value to Merck KGaA is limited and the decision was part of a rationalisation of the Merck KGaA development pipeline.
The decision was made as part of an "ongoing review and re-prioritisation of the company's R&D pipeline".
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.